Article

Santen moving

Santen Inc. is moving its U.S. corporate headquarters from Napa, CA, to Emeryville, CA, in July.

Napa, CA-Santen Inc. is moving its U.S. corporate headquarters from Napa, CA, to Emeryville, CA, in July. The company is a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd., Osaka, Japan.

“In the preparation of our new strategic plan, we can see that there will be substantial expansion of the organization, and we could not have accommodated this growth in the existing facility in Napa,” said Akihiro Tsujimura, chief operating officer of Santen Inc. “Since we will experience a significant demand for new staff, we believe that the new location will make it easier to recruit the highest-quality talent, as we will have increased access to the greater San Francisco Bay area biopharmaceutical talent pool.”

A secondary reason for the relocation, according to company officials, was the need for convenient access to international transportation due to increased interaction with the company’s employees in Japan and Europe.

Santen will occupy nearly 50,000 square feet on the top two floors of a 16-story building.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.